Drug intelligence / Profile preview

DWJ1507

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules

Overview

DWJ1507 is an investigational drug developed by Daewoong Pharmaceutical for the treatment of dyslipidemia, a condition characterized by abnormal levels of lipids in the blood. The precise mechanism of action and molecular target(s) for DWJ1507 have not been publicly disclosed. It is being evaluated in clinical trials as a potential therapy within the field of endocrinology and metabolic diseases, specifically targeting lipid disorders such as dyslipidemias[1][3][4]. As of early 2025, it has reached Phase 3 clinical development but has not received regulatory approval in any country[1][3].

Other names: DWJ 1507DWJ1507DWJ-1507

Targets

NPC1L1 (Niemann-pick C1-Like 1 transporter)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on DWJ1507.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWJ1507.

Explore the full profile